AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00877604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical placebo by oral route at the same dosing schedule
Trial: NCT00003852
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02257346
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline will be administered as a placebo immediately after delivery of the fetus and continue through 1 hour into recovery period
Trial: NCT02125682
Drug: atovastatin 10 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive 10 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 80 mg daily for 8 weeks
Trial: NCT02556320
Drug: anti-epileptic drug
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
Trial: NCT00707148
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.9% NaCl) administered as a single 0.5 mL intramuscular injection into the deltoid.
Trial: NCT03017404
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02093169
Drug: Part A: Lu AF35700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 30 mg single dose for one day; orally
Trial: NCT00712712
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of paracetamol (4 g / 24h) and patient-controlled analgesia (PCA).
Trial: NCT01772810
Drug: Human spinal cord stem cells.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human spinal cord stem cell implantation in paralysis patients due to a spinal cord injury.
Trial: NCT02044302
Drug: Analgesics
RxNorm normalized name: ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02093169
Drug: Part B: Lu AF35700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing: 10 mg for 3 days, 20 mg for 3 days, 45 mg on Day 7; orally
Trial: NCT02630966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride IV infusion
Trial: NCT04029584
Drug: Fluvastatin 20 MG
RxNorm normalized name: fluvastatin 20 MG
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one oral dose of fluvastatin (Lescol ) 20mg capsule
Trial: NCT00038402
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2 by vein on Days 1 and 4 for 4 cycles at 3-4 week intervals.
Trial: NCT04537078
Drug: Cetrotide Injectable Product
RxNorm normalized name: Cetrotide Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will used in the second arm for pituitary suppression in the second group daily when the biggest oocyte reaches size 14 mm till ovulation triggering
Trial: NCT02570308
Drug: IMCgp100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bispecific soluble HLA-A2 restricted gp100-specific T-cell receptor fused to anti-CD3
Trial: NCT01960413
Drug: Montelukast added to Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01960413
Drug: Placebo added to Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00357292
Drug: Azithromycin (T1225)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01109212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage form: tablet dosage: n.a. frequency: 2xplacebo b.i.d duration:12 weeks
Trial: NCT01750775
Drug: placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
Trial: NCT03266146
Drug: 36 Weeks Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 36 weeks. Follow-up duration is 24 weeks.
Trial: NCT03266146
Drug: 48 weeks Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in 48 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
Trial: NCT01116271
Drug: AZD6244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 or 75mg, capsules, PO, BID, 28 days
Trial: NCT03691519
Drug: Omega-3 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient in the treatment comparative arm will consume 3- 1g softgel vegetarian capsules of DHA-O per day as a single dose for 36 months; each 1g capsule of DHA-0 providing 324 mg DHA and 185 mg EPA (total daily DHA+EPA dose = 1.53 g/day).
Trial: NCT00144820
Drug: Injection of Hyaluronan or Saline
RxNorm normalized name: Rosula NS Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03762265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet Route of administration: Oral
Trial: NCT01805089
Drug: Melatonin 3 mg
RxNorm normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin vs. Placebo
Trial: NCT02287181
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: short acting opiate
Trial: NCT01153815
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02519374
Drug: PROMITOR® (including Maltodextrin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product dose 1
Trial: NCT02519374
Drug: PROMITOR® (including Maltodextrin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product dose 2
Trial: NCT02519374
Drug: PROMITOR® (including Maltodextrin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product dose 3
Trial: NCT04389229
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600mg/m2/day for 3 days ( on day -5, -4, -3)
Trial: NCT02245516
Drug: KPI-121 0.25% Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KPI-121 drug product will be supplied a 0.25% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
Trial: NCT02245516
Drug: KPI-121 1.0% Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KPI-121 drug product will be supplied a 1.0% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
Trial: NCT01452243
Drug: Vitamin D and calcium suplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacological intervention will be the daily administration of chewable tablets containing 800 IU of vitamin D and 1200 mg of calcium. They will be administered over 2 years during the months of November to April in order to avoid the influence of sunlight.
Trial: NCT00548678
Drug: intravenous diclofenac sodium (DIC075V)
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous diclofenac sodium
Trial: NCT00548678
Drug: ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous ketorolac
Trial: NCT00548678
Drug: oral diclofenac (Cataflam)
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral diclofenac (Cataflam)
Trial: NCT02065609
Drug: HER2 Positive Lesion Detection and Safety
RxNorm normalized name: scabies lesion lysate (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging
Trial: NCT01452880
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil is an ultra-short-acting oppioid, which is quickly metabolized by unspecific blood and tissue esterases
Trial: NCT01452880
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GROUP A (N = 114): patients assigned to this group received Remifentanil at infusion rate of 0.05 mcg / kg / min I.V. ; GROUP B (N = 114): in this group Remifentanil was administered at infusion rate of 0,1 mcg / kg / min I.V. Remifentanil was administered intravenously throughout ESWL procedure.
Trial: NCT00435331
Drug: sapropterin dihydrochloride (6R-BH4)
RxNorm normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2.5 mg/kg/day for two weeks, 5 mg/kg/day for two weeks, 10 mg/kg/day for four weeks, then 20 mg/kg/day for two days
Trial: NCT01467713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon sublingual (SL) placebo-matching tablets
Trial: NCT02832687
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients 50kg or more receive1000mg in 100milliliters of normal saline every 4 hours to a maximum dose 4000mg/24 hours. \<50kg receive 12.5mg/kg to a maximum of 75mg/kg/24 hours.
Trial: NCT02832687
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mL of normal saline every 4 hours to a maximum administration of 400mL
Trial: NCT01593774
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet melatonin 3 mg/day at 9 pm as intervention group
Trial: NCT01593774
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (with the same shape and taste as melatonin) at 9 pm as control group
Trial: NCT02019472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injections
Trial: NCT01563042
Drug: Intravenous (IV) single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2434735 administered as a single intervenous dose at the beginning of the study
Trial: NCT01563042
Drug: Subcutaneous (SC) single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2434735 administered as a single subcutaneous dose at the beginning of the study
Trial: NCT02974686
Drug: Mycophenolic Acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03283566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a pre-transplant placebo 30 days before TPAIT and will continue on the placebo for 3 months after surgery.
Trial: NCT00818766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received IV placebo for 48 hours post-operatively or until all chest tubes were removed, whichever occurred first.
Trial: NCT01178372
Drug: Probiotics(VSL#3)
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will receive VSL#3 (110 billion CFU)three times a day
Trial: NCT02568306
Drug: NNC0165-1562
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) single dose \[SD\] or multiple dose \[MD\] with daily dosing.
Trial: NCT02568306
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) single dose \[SD\]) or multiple dose \[MD\] with daily dosing.
Trial: NCT01861015
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02845024
Drug: Doxycycline Group
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral doxycycline 100mg was taken within 15 days
Trial: NCT02845024
Drug: placebo Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo was taken within 15 days
Trial: NCT00853008
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX)3 g/m2,IV, d1 (24h)in consolidation, cycles 1 and 2 MTX (15 mg/m2/wk, IM)in maintenance MTX 15 mg, IT
Trial: NCT00853008
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mercaptopurine 100 mg/m2, PO, d 1-5 in consolidation
Trial: NCT00853008
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 20 mg, IT d 1, 28, 49, 77, 105, 175, 203, 231, 259,287, 311 intrathecal
Trial: NCT01296087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule given once daily on Days 1 to 28
Trial: NCT01125189
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, oral, 0 mg, once daily, 24 weeks
Trial: NCT01343043
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy.
Trial: NCT03693131
Drug: Icosapent (MND-2119)
DrugBank: Icosapent (DB00159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icosapent (MND-2119) capsules.
Trial: NCT03693131
Drug: Icosapent (EPADEL CAPSULES 300)
RxNorm normalized name: Icosapent Ethyl Capsules
DrugBank: Icosapent (DB00159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icosapent (EPADEL CAPSULES 300) capsules.
Trial: NCT04248868
Drug: r-tPA
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse spray and infusion
Trial: NCT01496677
Drug: TR-701 FA 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral tablet of TR-701 FA to elderly subjects
Trial: NCT02562989
Drug: [18F]MK-6240, ~185 MBq
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dose of \~185 MBq \[18F\]MK-6240
Trial: NCT02562989
Drug: [18F]MK-6240, ~160 MBq
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dose of \~160 MBq \[18F\]MK-6240
Trial: NCT00976729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00128882
Drug: Anti-D
RxNorm normalized name: D-Gam Anti-D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT04756882
Drug: AbobotulinumtoxinA 500 UNT
RxNorm normalized name: abobotulinumtoxinA 500 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaerobic fermentation of the bacterium Clostridium botulinum produces botulinum toxin. A range of different C. Botulinum strains have been recognized; eight immunologically different serotypes (type A-H) are created and consist of botulinum neurotoxin complexed with a number of related proteins.~Neurotoxin type A preparations are the most widely used for therapeutic application. There are currently three leading botulinum neurotoxin type A (BoNT/A) products on the market in the Western Hemisphere: onabotulinumtoxinA (ONA; Botox/Vistabel, Allergan Inc., Irvine, CA, USA), abobotulinum toxin A (ABO; Dysport/Ipsen Limited, Slough Berkshire, UK), and incobotulinum toxin A (INCO; Xeomin/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany). In nature, BoNT-A is synthesized as macromolecular protein complexes
Trial: NCT00428246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02271334
Drug: Proventil® MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose 90 mcg, 2 inhalations
Trial: NCT03191383
Drug: Placebo (Formulation buffer S9b)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
Trial: NCT00766012
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16.
Trial: NCT00299325
Drug: Placebo (for Rimonabant)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral administration
Trial: NCT03442751
Drug: Test Article A
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin Ophthalmic Solution A
Trial: NCT03442751
Drug: Test Article B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin Ophthalmic Solution B
Trial: NCT03442751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Vehicle of Test Article
Trial: NCT01946620
Drug: Flutiform
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05468294
Drug: F16IL2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F16IL2 infusion will be always administered in 180 minutes i.v. on day 1, 8, 15 and 22 of each 28-days cycle.
Trial: NCT02179892
Drug: IV Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) acetaminophen 1000 mg every 8 hours for 8 doses.
Trial: NCT02179892
Drug: Oral Acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen 650 mg every 6 hours.
Trial: NCT02159131
Drug: GSK1265744
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 is available as 30 mg tablet to be taken along with 240 mL water
Trial: NCT03631446
Drug: Sodium Picosulfate, Magnesium Oxide and Citric Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination powder for oral solution
Trial: NCT01332344
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: asthma subjects newly prescribed inhaled corticosteroids in clinical practice
Trial: NCT00660517
Drug: MP29-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray one spray per nostril twice a day
Trial: NCT00660517
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo nasal spray one spray per nostril two times a day
Trial: NCT00519116
Drug: Rapamune® (Sirolimus)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04299880
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous
Trial: NCT04299880
Drug: 5Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous
Trial: NCT00526630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given placebo instead of active MPD.
Trial: NCT02123264
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid: 5 mg/year x 2 years
Trial: NCT01935141
Drug: Visipaque 320 non-ionic isoosmolar contrast agent
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Dose of Intravenous Iodixanol will be administered per CT scan.
Trial: NCT01422213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules; daily; orally
Trial: NCT01972776
Drug: QBM076
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied in 25 mg and 75 mg capsules
Trial: NCT04146441
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX Regime according to Norwegian national guidelines
Trial: NCT01862978
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01862978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01087125
Drug: No Interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Interventions
Trial: NCT01355588
Drug: Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Ketorolac Tromethamine with 4% Lidocaine HCl IN
Trial: NCT01355588
Drug: Ketorolac Tromethamine with 5% Lidocaine HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Ketorolac Tromethamine with 5% Lidocaine HCl IN
Trial: NCT01355588
Drug: 30 mg Ketorolac Tromethamine with 6% Lidocaine HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Ketorolac Tromethamine with 6% Lidocaine HCl IN